Kymera Therapeutics(US:KYMR)2025-11-04 12:10Financial Performance - Kymera Therapeutics reported collaboration revenues of $2.8 million for Q3 2025, down from $3.7 million in Q3 2024, all attributable to collaboration with Gilead Sciences[8] - The net loss for Q3 2025 was $82.2 million, compared to a net loss of $62.5 million in Q3 2024[12] - Net loss attributable to common stockholders for Q3 2025 was $82,175,000, compared to a net loss of $62,487,000 in Q3 2024, representing a 31.5% increase in losses[19] - Net loss per share attributable to common stockholders was $0.94 for Q3 2025, compared to $0.82 for Q3 2024[19] - Total operating expenses for Q3 2025 were $95,285,000, an increase of 25.5% from $75,865,000 in Q3 2024[19] - For the nine months ended September 30, 2025, total operating expenses were $287,844,000, up 30.5% from $220,558,000 in the same period of 2024[19] - Total other income for Q3 2025 was $10,346,000, an increase from $9,637,000 in Q3 2024[19] Research and Development - Research and development expenses increased to $74.1 million in Q3 2025 from $60.4 million in Q3 2024, primarily due to investments in the STAT6 program and growth in the R&D organization[10] - The KT-621 BroADen Phase 1b trial in atopic dermatitis has completed enrollment and dosing, with data expected in December 2025[1] - The KT-621 BROADEN2 Phase 2b trial in atopic dermatitis has been initiated, with topline data expected by mid-2027, involving approximately 200 patients[4] - The KT-579 IND-enabling studies have been completed, with a Phase 1 clinical trial expected to start in early 2026[1] - The company is on track to initiate the BREADTH Phase 2b trial in asthma patients in Q1 2026, which is expected to accelerate KT-621 development[4] Expenses - General and administrative expenses rose to $17.3 million in Q3 2025 compared to $15.5 million in Q3 2024, driven by increased legal and professional service fees[11] - General and administrative expenses rose to $17,336,000 in Q3 2025, compared to $15,455,000 in Q3 2024, reflecting a 12.1% increase[19] - Impairment of long-lived assets was recorded at $3,855,000 in Q3 2025, while there was no impairment in Q3 2024[19] Leadership Changes - Kymera appointed Brian Adams as Chief Legal Officer and Corporate Secretary in September 2025 to lead legal and corporate governance functions[7] Cash Position - As of September 30, 2025, Kymera had $978.7 million in cash and cash equivalents, providing a runway into the second half of 2028[12] Stock Information - The weighted average common stocks outstanding for Q3 2025 was 87,300,286, compared to 76,125,975 in Q3 2024[19]